BB BIOTECH N Logo
CH0038389992
A0NFN3
BBZA.DE

BB BIOTECH N

Cargando cotizaciones...

Previsión

No hay datos de analistas disponibles para esta empresa.

Debates en la comunidad

  • Split BB Biotech 2016

    Rainer Rainer I en Schnack

    0 3

  • BB Biotech makes twelve new investments after sale of Crinetics and Nuvalent

    BB Biotech realised about CHF 280 million in Q3 by selling Crinetics Pharmaceuticals and Nuvalent and immediately deployed the proceeds into twelve new positions. Larger purchases included Biogen, Incyte and Axsome Therapeutics; Alnylam was re-added to the portfolio after a price drop. Other new investments cover advanced development programmes such as Kodiak Sciences, Summit Therapeutics, LB Pharmaceuticals and Bicara, as well as smaller starter positions in Alto Neuroscience, Yarrow Bioscience and Eupraxia. Private holdings remain limited, while BB Biotech sees room to expand positions if clinical evidence is positive; the stock has picked up momentum again after a period of consolidation. » Más en deraktionaer.de


  • BB Biotech expands portfolio and adds twelve new positions

    BB Biotech expanded its portfolio by twelve new holdings in the third quarter and reinvested around CHF 280 million from takeovers. The new additions range from established biotech companies with product revenues to clinical-stage developers with upcoming milestones. The purchases aim to find stocks whose market valuations do not yet fully reflect their scientific, clinical and commercial potential. » Más en finanzen.net


  • BB Biotech posts profit again in third quarter and sees targeted investment opportunities

    BB Biotech recorded a profit of CHF 175 million in the third quarter, marking the second consecutive profitable quarter. The net asset value rose 5.6% in CHF during the quarter, and the company reports clinical and regulatory progress at portfolio companies. After the September correction, BB Biotech sees targeted buying opportunities in stocks whose prices have fallen despite unchanged clinical prospects; further milestones are expected in the fourth quarter. » Más en finanzen.net


  • BB Biotech: AI could trigger a new innovation-driven growth cycle in the biotech sector

    BB Biotech and Medpace are among the stocks traders are currently backing, as AI-supported models could accelerate drug development and spark broader innovation across the sector. After years dominated by GLP-1 and individual blockbusters, multiple biotech companies could now benefit from more efficient drug discovery and new discoveries. The article names three biotech stocks at 52-week highs that traders should keep an eye on. » Más en finanzen.net


  • BB Biotech: comeback gains momentum as analysts recommend selling numerous stocks

    Last trading week, numerous analysts advised exiting various stocks and issued multiple sell recommendations. At the same time, BB Biotech reported a stronger comeback with solid quarterly results and a portfolio that outperforms the industry index, while the stock still lags its intrinsic value. » Más en finanzen.net

En 2026, BB BIOTECH N ya ha pagado 2,46 € en dividendos. El último pago fue en marzo.

Datos financieros de la empresa

En el último trimestre, BB BIOTECH N tuvo unos ingresos de 178,64 M € y un beneficio neto de 175,04 M €
(EUR) septiembre de 2026
YoY
Ingresos 178,64 M 751,45 %
Beneficio bruto 178,64 M 751,45 %
Beneficio neto 175,04 M 60,82 %
EBITDA 173,87 M 61,09 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
3143,51 M €
Número de acciones
55,15 M
Máximo/mínimo de 52 semanas
60,80 € - 33,40 €
Rentabilidad por dividendo
4,27 %
Dividendos TTM
2,46 €
Beta
0,65
Ratio P/E
2,70
Ratio PEG
0,00
Ratio P/B
0,89
Ratio P/S
13,22

Perfil de la empresa

BB Biotech AG es un fondo de renta variable lanzado y gestionado por Bellevue Asset Management AG. El fondo invierte en los mercados de renta variable pública de todo el mundo. Invierte principalmente en acciones de empresas dedicadas a medicamentos y diagnósticos basados en la biotecnología moderna. El fondo emplea un análisis fundamental para construir su cartera. BB Biotech AG se constituyó el 9 de noviembre de 1993 y tiene su domicilio en Suiza.

Nombre
BB BIOTECH N
CEO
Daniel Koller
Sede Kusnacht,
Suiza
Sitio web
Sector
Salud
Industria
Biotecnología
Salida a bolsa
04/01/2000
Empleados 10

Símbolos bursátiles

Bolsa Símbolo
XETRA
BBZA.DE
SIX
BION.SW
Hamburg
BBZA.HM
London
0JYO.L
München
BBZA.MU
🍪

Parqet  usa cookies. Más información